Global Eptacog Alfa (rFVIIa) Market Growth 2025-2031
Description
The global Eptacog Alfa (rFVIIa) market size is predicted to grow from US$ 1287 million in 2025 to US$ 1702 million in 2031; it is expected to grow at a CAGR of 4.8% from 2025 to 2031.
Recombinant human coagulation factor VIIa is a drug from Novo Nordisk for bleeding episodes and prevention of bleeding during surgical procedures or invasive procedures in the following patient groups:
1. Inhibitors of coagulation factor VIII or IX 5BU in congenital hemophilia patients; 2. Congenital hemophilia patients who are expected to have a high memory response to injection of coagulation factor VIII or coagulation factor IX; 3. Acquired blood 4. Patients with congenital FVII deficiency; 5. Patients with thrombocytopenia who have GP IIb-IIIa and/or HLA antibodies and past or present ineffective or poor platelet transfusions.
Novo Nordisk is the largest manufacturers of eptacog alfa (rFVIIa) in the world, has a share about 92%. Other players include LFB SA, GENERIUM,Northland-bio, and Northland-bioi, etc. The key players are mainly located in Europe, North America, China, and Japan. In terms of product, freeze-dried preparation is the largest segment, with a share over 52%. And in terms of application, the largest application is hemophilia, with a share over 48%, followed by acquired hemophilia.
LP Information, Inc. (LPI) ' newest research report, the “Eptacog Alfa (rFVIIa) Industry Forecast” looks at past sales and reviews total world Eptacog Alfa (rFVIIa) sales in 2024, providing a comprehensive analysis by region and market sector of projected Eptacog Alfa (rFVIIa) sales for 2025 through 2031. With Eptacog Alfa (rFVIIa) sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Eptacog Alfa (rFVIIa) industry.
This Insight Report provides a comprehensive analysis of the global Eptacog Alfa (rFVIIa) landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Eptacog Alfa (rFVIIa) portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Eptacog Alfa (rFVIIa) market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Eptacog Alfa (rFVIIa) and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Eptacog Alfa (rFVIIa).
This report presents a comprehensive overview, market shares, and growth opportunities of Eptacog Alfa (rFVIIa) market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Freeze-dried Preparation
Freeze-dried Powder
Segmentation by Application:
Hemophilia
Acquired Hemophilia
Factor VII Deficiency
Glanzmann Thrombasthenia (GT)
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Novo Nordisk
LFB SA
GENERIUM
Northland-bio
CSL
Shire (Takeda)
Bayer
Key Questions Addressed in this Report
What is the 10-year outlook for the global Eptacog Alfa (rFVIIa) market?
What factors are driving Eptacog Alfa (rFVIIa) market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Eptacog Alfa (rFVIIa) market opportunities vary by end market size?
How does Eptacog Alfa (rFVIIa) break out by Type, by Application?
Please note: The report will take approximately 2 business days to prepare and deliver.
Recombinant human coagulation factor VIIa is a drug from Novo Nordisk for bleeding episodes and prevention of bleeding during surgical procedures or invasive procedures in the following patient groups:
1. Inhibitors of coagulation factor VIII or IX 5BU in congenital hemophilia patients; 2. Congenital hemophilia patients who are expected to have a high memory response to injection of coagulation factor VIII or coagulation factor IX; 3. Acquired blood 4. Patients with congenital FVII deficiency; 5. Patients with thrombocytopenia who have GP IIb-IIIa and/or HLA antibodies and past or present ineffective or poor platelet transfusions.
Novo Nordisk is the largest manufacturers of eptacog alfa (rFVIIa) in the world, has a share about 92%. Other players include LFB SA, GENERIUM,Northland-bio, and Northland-bioi, etc. The key players are mainly located in Europe, North America, China, and Japan. In terms of product, freeze-dried preparation is the largest segment, with a share over 52%. And in terms of application, the largest application is hemophilia, with a share over 48%, followed by acquired hemophilia.
LP Information, Inc. (LPI) ' newest research report, the “Eptacog Alfa (rFVIIa) Industry Forecast” looks at past sales and reviews total world Eptacog Alfa (rFVIIa) sales in 2024, providing a comprehensive analysis by region and market sector of projected Eptacog Alfa (rFVIIa) sales for 2025 through 2031. With Eptacog Alfa (rFVIIa) sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Eptacog Alfa (rFVIIa) industry.
This Insight Report provides a comprehensive analysis of the global Eptacog Alfa (rFVIIa) landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Eptacog Alfa (rFVIIa) portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Eptacog Alfa (rFVIIa) market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Eptacog Alfa (rFVIIa) and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Eptacog Alfa (rFVIIa).
This report presents a comprehensive overview, market shares, and growth opportunities of Eptacog Alfa (rFVIIa) market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Freeze-dried Preparation
Freeze-dried Powder
Segmentation by Application:
Hemophilia
Acquired Hemophilia
Factor VII Deficiency
Glanzmann Thrombasthenia (GT)
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Novo Nordisk
LFB SA
GENERIUM
Northland-bio
CSL
Shire (Takeda)
Bayer
Key Questions Addressed in this Report
What is the 10-year outlook for the global Eptacog Alfa (rFVIIa) market?
What factors are driving Eptacog Alfa (rFVIIa) market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Eptacog Alfa (rFVIIa) market opportunities vary by end market size?
How does Eptacog Alfa (rFVIIa) break out by Type, by Application?
Please note: The report will take approximately 2 business days to prepare and deliver.
Table of Contents
96 Pages
- *This is a tentative TOC and the final deliverable is subject to change.*
- 1 Scope of the Report
- 2 Executive Summary
- 3 Global by Company
- 4 World Historic Review for Eptacog Alfa (rFVIIa) by Geographic Region
- 5 Americas
- 6 APAC
- 7 Europe
- 8 Middle East & Africa
- 9 Market Drivers, Challenges and Trends
- 10 Manufacturing Cost Structure Analysis
- 11 Marketing, Distributors and Customer
- 12 World Forecast Review for Eptacog Alfa (rFVIIa) by Geographic Region
- 13 Key Players Analysis
- 14 Research Findings and Conclusion
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
